Ocular Therapeut Stock Price, News & Analysis

Ocular Therapeutix (NASDAQ: OCUL) announced the imminent closure of enrollment for SOL-R, its second registrational trial evaluating AXPAXLI™ for wet age-related macular degeneration (wet AMD). The trial, targeting at least 555 subjects across approximately 100 sites in the U.S., Argentina, India, and Australia, will evaluate AXPAXLI dosed every 6 months versus aflibercept every 8 weeks. This follows the completion of SOL-1, the company's first registrational trial, in December 2024, which remains on track for top-line readout in Q1 2026. Both FDA-aligned trials are designed to support an NDA submission for AXPAXLI, with potential for a superiority claim and 6- to 12-month dosing schedule. The primary endpoint of SOL-R aims to demonstrate non-inferiority in mean change in best corrected visual acuity from baseline between AXPAXLI and aflibercept at Week 56.

Ocular Therapeutix (NASDAQ: OCUL) has announced its participation in four major investor conferences in May 2025. The company's Executive Chairman, President and CEO, Dr. Pravin U. Dugel, will present at:

• RBC Capital Markets Global Healthcare Conference (May 20, 2:35 PM ET)
• HC Wainwright BioConnect Investor Conference (May 20, 4:30 PM ET)
• Mizuho Neuro & Ophthalmology Summit (May 21, one-on-one meetings)
• Stifel Virtual Ophthalmology Forum (May 27, 3:00 PM ET)

Live webcasts for the RBC Capital Markets, HC Wainwright, and Stifel fireside chats will be available on the company's website under the Events and Presentations section.

Ocular Therapeutix (NASDAQ: OCUL) reported Q1 2025 financial results and provided updates on its AXPAXLI™ development programs. The company's SOL trials for wet AMD are progressing well, with SOL-1 showing exceptional retention and on track for 1Q 2026 topline data. SOL-R enrollment remains strong following optimization to ~555 subjects. The company received positive FDA feedback for AXPAXLI in NPDR and is planning next steps for NPDR and DME indications. Financially, Ocular reported $349.7M in cash as of March 31, 2025, providing runway into 2028. Q1 2025 results showed total revenue of $10.7M, down 27.6% YoY, primarily due to decreased DEXTENZA sales. The company posted a net loss of $64.1M ($0.38 per share), compared to $64.8M loss in Q1 2024. R&D expenses increased to $42.9M from $20.7M due to clinical trial costs.

Ocular Therapeutix (NASDAQ: OCUL) has announced its participation in major investor and scientific conferences in May 2025. The company's leadership team, including Executive Chairman Dr. Pravin Dugel, will present at the Citizens JMP Life Sciences Conference (May 7) and Bank of America Global Healthcare Conference (May 13).

The company will have significant presence at key scientific events including Eyecelerator, ARVO 2025, and Retina World Congress. Notable presentations will focus on their axitinib hydrogel (OTX-TKI) research for diabetic retinopathy and macular degeneration. Multiple studies will be presented, including results from the HELIOS trial and research on retinal leakage assessment.

Key executives participating include Chief Medical Officer Dr. Waheed, Chief Business Officer Saroj, and Chief Strategy Officer Dr. Nayak. The presentations will showcase Ocular's advances in novel drug delivery approaches for retinal conditions.

Ocular Therapeutix (NASDAQ: OCUL) announced it will release its first quarter 2025 financial results on Monday, May 5, 2025 at 7:00 AM Eastern Time. The biopharmaceutical company, focused on redefining the retina experience, stated it will not host a Q1 2025 conference call but plans to resume quarterly earnings calls starting with Q2 2025 results.

Ocular Therapeutix (NASDAQ: OCUL) has announced inducement awards for two new employees, including Thomas J. Cella, appointed as Executive Director of Payer Access. The awards, granted on April 7, 2025, include:

For Mr. Cella:

• Non-statutory stock option to purchase 26,000 shares
• Restricted stock unit award for 8,500 shares

For the non-executive employee:

• Non-statutory stock option to purchase 23,500 shares
• Restricted stock unit award for 7,700 shares

The stock options have a $6.30 per share exercise price and a ten-year term, vesting over four years. The restricted stock units vest over three years in equal annual installments, beginning April 7, 2026. These awards were granted under Ocular's 2019 Inducement Stock Incentive Plan in compliance with Nasdaq Listing Rule 5635(c)(4).

Ocular Therapeutix (NASDAQ: OCUL), a biopharmaceutical company focused on retina treatments, has announced its participation in two major investor conferences this April. The first event is the 24th Annual Needham Virtual Healthcare Conference, where Dr. Pravin U. Dugel, Executive Chairman, President and CEO, will present on Monday, April 7, 2025, at 3:00 PM ET in a virtual format.

The second event is the Piper Sandler Spring Biopharma Symposium in Boston, MA, scheduled for Thursday, April 17, 2025, where the company will host one-on-one meetings with investors. Interested parties can access a live webcast of the Needham presentation through the Events and Presentations section of Ocular's Investor Relations webpage.

Ocular Therapeutix (NASDAQ: OCUL) has announced inducement awards for a new employee under its 2019 Inducement Stock Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4). The grants, effective March 3, 2025, include:

• A non-statutory stock option to purchase 48,000 shares at market price
• A restricted stock unit (RSU) award for 15,500 shares

The stock option has a 10-year term with a 4-year vesting schedule: 25% vesting on March 3, 2026, and the remainder monthly over three years. The RSU award vests over three years in equal annual installments, starting March 3, 2026. Both awards require continued employment with Ocular through vesting dates.

Ocular Therapeutix (NASDAQ: OCUL) reported Q4 and full year 2024 results, highlighting significant progress in their AXPAXLI registrational program for wet AMD treatment. The company announced FDA approval for re-dosing at Weeks 52 and 76 in the SOL-1 trial, with primary endpoint data expected in Q1 2026.

Key financial highlights include:

• Cash position of $392.1M as of December 31, 2024, funding operations into 2028
• Q4 2024 total revenue of $17.1M, up 15.4% year-over-year
• Full year 2024 revenue of $63.7M, a 9.0% increase from 2023
• Q4 2024 net loss of $(48.4M), or $(0.29) per share

The company reduced SOL-R trial size to 555 subjects from 825, potentially accelerating registration timelines. FDA feedback on AXPAXLI in NPDR and DME is expected in 1H 2025.